Romosozumab for the treatment of osteoporosis
Osteoporosis and Sarcopenia
;
: 11-15, 2018.
Article
Dans Anglais
| WPRIM
| ID: wpr-741775
ABSTRACT
Romosozumab, a specific inhibitor of sclerostin, is a unique approach to therapy for postmenopausal osteoporosis and related disorders. The elucidation of sclerostin deficiency as the molecular defect of syndromes of high bone mass with normal quality, and the pivotal role of sclerostin as a mediator of osteoblastic activity and bone formation, provided the platform for the evaluation of inhibitors of sclerostin to activate bone formation. An extensive preclinical program and 2 large fracture endpoint trials with romosozumab, a sclerostin-binding antibody, have been completed. This review will highlight the results of those studies and describe the current status of romosozumab as a potential therapy for osteoporosis.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Ostéoblastes
/
Ostéogenèse
/
Ostéoporose
/
Ostéoporose post-ménopausique
Limites du sujet:
Femelle
/
Humains
langue:
Anglais
Texte intégral:
Osteoporosis and Sarcopenia
Année:
2018
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS